📦 At-home kits now available.Order your kit →
Guide
Review
Beginner
For Patients

Microclots Treatment: Every Approach Studied and the Evidence

Tim Ottowitz Published 6 min read

Short answer

No treatment has been shown in a randomized trial to remove microclots or improve outcomes for them. Approaches studied include triple anticoagulant and antiplatelet therapy, aspirin, enzymes, apheresis, DNase and ultrasound. Most evidence is uncontrolled reports or lab work; a 2023 Cochrane review found no randomized trials of plasmapheresis, and a 2025 plasma exchange trial found no benefit. Any decision belongs with your clinician.

Laboratory illustration related to enzymes breaking down protein clots

Key takeaways

  • 1A 2023 Cochrane review found no randomized trials of plasmapheresis for microclots, and no treatment for them has been proven.
  • 2The only clinical data for triple therapy is an uncontrolled 91-patient preprint; the bleeding risk is real.
  • 3Nattokinase and lumbrokinase have lab and healthy-volunteer data, but the only before-and-after microclot measurements in people are two patients in an unpublished master's thesis.
  • 4Ultrasound lysis is a lab-on-chip experiment, not a treatment anyone can receive.
  • 5Haematologists argue the particles are not clots, so anticoagulants are not plausible treatments; proponents disagree.

No treatment has been proven to remove microclots or to improve outcomes for people who have them, including any fibrinaloid microclots treatment or long covid microclots treatment you may see advertised. Almost every option below is an uncontrolled report, a lab experiment or a medicine used on a hypothesis; the one randomized trial, of plasma exchange, found no benefit, and the 2023 Cochrane review found no randomized trials of plasmapheresis to judge. This page lays all of them side by side so you can see what has actually been studied.

What does the best evidence say about microclots treatment?

The Cochrane review (Fox, Hunt, Ariëns and colleagues, 2023) looked for randomized trials of plasmapheresis to remove amyloid fibrin(ogen) particles in post-COVID condition and found none. It also found five lab studies, three based on images that didn't quantify particles, and said they were insufficient to link the particles to the condition. Its conclusion: plasmapheresis for this shouldn't be used outside a well-conducted randomized trial.

That review is part of a live disagreement. Haematologists including Hunt and colleagues (2024) and Connors and Ariëns (2023) argue the evidence doesn't support persistent clotting as the cause of long COVID and that unlicensed antithrombotic use isn't justified. Kell, Khan and Pretorius replied that the critique misread their data. A 2024 study of 104 ICU patients also found amyloid-fibrinogen microclots in 42.3% on admission, linked to sepsis and to higher risks of DIC and death (Schofield et al.), so the particles are a real finding. What they mean for treatment is the open question. For the background debate, see are microclots real and what microclots are.

Every approach that has been studied or tried

ApproachWhat it isBest published evidenceStudy type and sizeMain riskDeeper article
Triple anticoagulant and antiplatelet therapyClopidogrel, aspirin and apixaban, plus a stomach protectorReported symptom and microclot improvementUncontrolled preprint, 91 patientsSerious bleedingTriple therapy
Single antiplatelet (aspirin)Low-dose platelet inhibitorOnly studied inside the triple regimen; we found no microclot study of aspirin aloneNone for aspirin aloneStomach and other bleedingAspirin for microclots
Nattokinase, lumbrokinase, serrapeptaseOral enzyme supplementsNattokinase degraded lab-made clots in a preprint; no significant effect on plasma-derived clots in a 2025 lab study; a single dose changed clotting markers in healthy menLab studies; 12 healthy volunteersBleeding, supplement variabilityNattokinase and lumbrokinase
H.E.L.P. apheresis or DFPPFiltering plasma outside the bodyFibrinogen fell about 70% in patients who improvedUncontrolled cohorts; no randomized trial of this methodProcedure risks, costPlasmapheresis
DNaseEnzyme that digests the DNA scaffold of NETsDissolves NETs in the labLab and hospital-patient studies, no symptom trialUnknown in this useDNases and NETs
Ultrasound lysisLow-frequency sound waves on clotsClot size reduced in a lab-on-chipIn vitro, porcine plasma, n = 2 to 3Not applicable to people yetCovered below

Do blood thinners remove microclots?

Not shown. The 91-patient triple therapy preprint tested clopidogrel, aspirin and apixaban, with microclots stained with Thioflavin T before and after. It had no control group and wasn't peer reviewed, so improvement can't be pinned on the drugs. The critics' point is sharper: if the particles are amyloid rather than true thrombi, drugs that block clotting have no obvious target.

Bleeding is the known cost. Seek urgent care for black stools, vomiting blood, a sudden severe headache or bleeding that won't stop. Whether to take any blood thinner is your clinician's decision.

Can microclots be dissolved with enzymes?

In test tubes, partly. A 2025 lab-on-chip study found that, without ultrasound, none of three enzymes significantly shrank plasma-derived microclots, including nattokinase. In healthy volunteers, a single oral dose in 12 men changed D-dimer and clotting times within normal ranges. Only one unpublished thesis has measured microclots in people before and after nattokinase, in two patients with no control group.

Some people report symptom flares after starting enzymes. Our guide to flare versus bleeding explains which signs need urgent care. For other supplements, see supplements for microclots.

Next step

Want to see what's in your own blood sample?

Our at-home amyloid fibrin test uses Thioflavin T fluorescence microscopy and gives you a Videographic Microscopy Report to share with your doctor.

Is apheresis worth it for microclots?

The evidence is split by design. In Dresden, apheresis patients who improved had fibrinogen fall about 70% and fibrin fibres largely disappear on dark-field microscopy, but that was an uncontrolled biomarker study. In the opposite direction, a 2025 randomized, sham-controlled trial in 50 people found plasma exchange safe but no better than sham for post-COVID condition. That's plasma exchange, not DFPP or H.E.L.P., so it doesn't settle those methods.

A DFPP-based program in Mexico is in development and isn't available yet. Our plasmapheresis guide covers what DFPP removes and who offers it.

What about ultrasound and other lab ideas?

A 2025 paper (Rasouli, Hartl and Konecky) exposed plasma-derived microclots to focused ultrasound in a lab-on-chip model. At 150 kHz, clot size fell up to three-fold, with small samples and no blood flow, using porcine plasma. All three authors work for the company behind the device. It's a proof of concept; no patient has been treated this way.

How do you treat microclots, practically?

Start with what you can verify. Microclots have no validated clinical test or reference range, so a result is research-grade information, not a diagnosis; see how to test for microclots. Sudden chest pain, severe breathlessness, a swollen painful leg, one-sided weakness or confusion could be a large clot (DVT, pulmonary embolism or stroke) and need emergency care whatever any microclot result shows.

For the symptoms themselves, your clinician can assess standard causes and options that don't depend on the microclot hypothesis. If you're considering any treatment above, ask what outcome you'd measure, who monitors bleeding risk, and what it costs.

Where does our test fit?

Some people want a baseline before talking to a clinician. Our amyloid test is an at-home finger-prick dried blood sample, mailed to a partner lab in Mexico City, stained with Thioflavin T and imaged by microscopy. It's not a diagnosis, and it isn't validated against the venous platelet-poor-plasma method used in published research. We don't claim that results change care. The method is explained in the amyloid fibrin test.

A related question is whether the particles clear without any treatment, which we cover in do microclots go away.

Frequently asked questions

How do you treat microclots?

There is no proven treatment. Clinics use anticoagulant and antiplatelet combinations, enzyme supplements or apheresis, but the evidence is uncontrolled reports and lab studies. A 2023 Cochrane review found no randomized trials of apheresis. Whether any option is reasonable for you is a decision to make with your clinician, who can weigh bleeding risk and your other conditions.

Can microclots be dissolved?

In the lab, some things break down microclot-like particles, including ultrasound in a 2025 lab-on-chip study and nattokinase in a test-tube preprint. In people, nobody has shown microclots can be dissolved. Patient microclots also resisted a first round of trypsin digestion in published work, which suggests they are hard to break down.

What is the best treatment for microclots in long covid?

No treatment has earned that title. None has been proven in a randomized trial for microclots. A 2025 randomized trial of plasma exchange in 50 people with post-COVID condition found it safe but showed no improvement over sham. Talk with a clinician about managing symptoms, which is a different question from removing microclots.

Do blood thinners remove microclots?

Not shown. The one published dataset, an uncontrolled preprint of 91 patients, reported fewer microclots and better symptoms after triple therapy, but it had no control group. Haematologists argue anticoagulants shouldn't work if the particles aren't true clots. Blood thinners carry bleeding risks, so they shouldn't be started or combined without a clinician.

Is apheresis worth it for microclots?

The evidence doesn't yet say. The Cochrane review advised against plasmapheresis for microclots outside randomized trials, and a 2025 sham-controlled trial of plasma exchange in post-COVID condition found no benefit. Small uncontrolled apheresis studies report improvement in some patients. It's costly and invasive, so weigh it with a clinician.

Sources

  1. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition. Cochrane Database of Systematic Reviews, 2023
  2. Challenging the current hypothesis that thrombosis is responsible for the post-COVID-19 condition. Research and Practice in Thrombosis and Haemostasis, 2024
  3. Uncertainties about the roles of anticoagulation and microclots in post-acute sequelae of SARS-CoV-2 infection. Journal of Thrombosis and Haemostasis, 2023
  4. Fibrinaloid microclots in long COVID: assessing the actual evidence properly. Research and Practice in Thrombosis and Haemostasis, 2024
  5. Treatment of Long COVID symptoms with triple anticoagulant therapy. Research Square (preprint), 2023
  6. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, 2015
  7. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Molecular Psychiatry, 2023
  8. Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial. Nature Communications, 2025
  9. Low-intensity ultrasound lysis of amyloid microclots in a lab-on-chip model. Frontiers in Bioengineering and Biotechnology, 2025
  10. Investigation of the synergistic effect of enzymatic and ultrasound-induced amyloid microclot degradation. Journal of Thrombosis and Thrombolysis, 2026
  11. Microclots, as defined by amyloid-fibrinogen aggregates, predict risks of disseminated intravascular coagulation and mortality. Blood Advances, 2024

At-Home Amyloid Test

Get Your Amyloid Test Kit Today

Simple at-home collection. Results in days.

    Next steps

    Tim Ottowitz

    Tim Ottowitz

    Founder & Research Lead

    Tim Ottowitz founded Amyloid Test and writes its Science Hub, turning fibrin amyloid and spike protein research into plain-language guides that stay close to the published evidence.

    Keep reading

    Illustration of fibrin strands forming a clot, the mesh that anticoagulant and antiplatelet drugs act on in different ways
    Guide
    Review

    Aspirin for Microclots: What the Evidence Shows and Doesn't

    Does aspirin help microclots? An antiplatelet that doesn't break down fibrin, with no trial in Long COVID. What studies found and the bleeding risks.

    Tim OttowitzNov 18, 2026
    6m
    Illustration of fibrin strands forming a clot, the target of anticoagulant and antiplatelet drugs
    Guide
    Observational

    Triple Therapy for Long COVID: 2026 Evidence and Bleeding Risks

    What triple anticoagulant therapy for long COVID involves, what the only published cohort found, why haematologists object, and the bleeding risks.

    Tim OttowitzOct 16, 2026
    6m
    Abstract illustration of green enzyme shapes next to a hexagonal lattice breaking into fragments
    Guide
    Review

    Supplements for Microclots: Which Have Any Evidence?

    Supplements for microclots ranked by evidence: nattokinase, lumbrokinase, serrapeptase and bromelain, what was tested in labs and what in people.

    Tim OttowitzNov 18, 2026
    7m